Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter: The Future of Value-Based Agreements

Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors

Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout

MMIT Reality Check on Narcolepsy (May 2020)

Perspectives on Surge of Mental Health Meds Use Amid COVID-19

Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?

Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently

MMIT Reality Check on Low Testosterone (May 2020)

Trends That Matter for Medical-Benefit Drug Spending

Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization

Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead

MMIT Reality Check on Pain Narcotic Opioid (May 2020)

Perspectives on Coronavirus Antibody Testing

Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)

Trends That Matter for Biosimilar Medications Cost Savings

Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift

Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)

Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19

Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend

Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2020)

Trends That Matter for Bipolar Disorder Medications

Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth

Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2020)

Perspectives on COVID-19 Outbreak's Impact on Drug Supply

Radar On Market Access: Slow Biosimilar Adoption and Opaque Markets Impede Potential Savings

Radar On Market Access: PBMs Use Dispensing Limits to Halt Hoarding of Trump-Touted Malaria Drugs

MMIT Reality Check on Opioid Dependence (Apr 2020)

Trends That Matter for Cost Impact of Coronavirus Treatment

Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection

MMIT Reality Check on COPD (Apr 2020)

Perspectives on New Generic HIV Drug

Radar On Market Access: Congress Could Pass Medicare Part D Reform Even Amid COVID-19 Outbreak

MMIT Reality Check on Glaucoma (Mar 2020)

Trends That Matter for Asthma Medications

Radar On Market Access: ACA Plans and Medicaid May See Enrollment Growth Amid COVID-19 Pandemic

Radar On Market Access: Questions Remain About Cost Impact of Coronavirus Treatment

MMIT Reality Check on Major Depressive Disorder (Mar 2020)

Perspectives on Legality of Closed Medicaid Formularies

Radar On Market Access: COVID-19 Outbreak Could Impact Drug Supply Long-Term

Radar On Market Access: Insurers, Pharma Spar Over Copay Accumulator Provision

MMIT Reality Check on Hereditary Angioedema (Mar 2020)

Trends That Matter for Diabetes Drug Costs

Radar On Market Access: Insurers Deploy Array of Strategies to Manage Asthma

Radar On Market Access: Florida Saw Strong MA, Individual Results and More Consolidations

MMIT Reality Check on HIV (Mar 2020)

Perspectives on ACA Exchange Draft Regulation

Radar On Market Access: New Generic HIV Drug May Impact PrEP Coverage, Not HIV Coverage

Radar On Market Access: Tenn. Blues’ White Bagging Policy Sees Pushback from Providers

MMIT Reality Check on Rheumatoid Arthritis (Feb 2020)

Trends That Matter for Nebraska Medicaid Expansion

Radar on Market Access: Future of Medicaid Work Requirements Dims After Arkansas Demo Is Struck Down Again

Radar On Market Access: CVS Touts Aetna’s Contribution; Molina Exchange Business Stumbles

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)

Perspectives on Part D Reform in 2020

Radar On Market Access: Payers Try New Strategies to Control Diabetes Drug Costs

Radar On Market Access: Some Experts Question Legality of Closed Medicaid Formularies

MMIT Reality Check on Neutropenia (Feb 2020)

Trends That Matter for Kansas Medicaid Expansion

Radar On Market Access: ACA Exchange Draft Regulation Drops

Radar On Market Access: New Oncology Biosimilar Launches Could Prompt Preferencing

MMIT Reality Check on Multiple Sclerosis (Feb 2020)

Perspectives on Consolidated PBMs in 2020

Radar On Market Access: Sanofi Backs Away From U.S. PCSK9 Market, While Novartis Bets Big With Inclisiran

Radar on Market Access: Nebraska Proposes A Two-Tiered Medicaid Expansion

MMIT Reality Check on Immune Globulin (PID) (Jan 2020)

Radar on Market Access: Disappointing MCOs, Supreme Court Won't Expedite Obamacare Decision

Radar on Market Access: Could Part D Reform Move Forward in 2020?

MMIT Reality Check on Epilepsy (Jan 2020)

Perspectives on MA Supplemental Benefits

Radar on Market Access: Supreme Court to Determine States' Ability to Regulate PBMs

Radar on Market Access: Kansas Works Out Medicaid Expansion Deal

MMIT Reality Check on Prostate Cancer (Jan 2020)

Trends That Matter for New Multiple Sclerosis Value-Based Contract

Radar on Market Access: State Lawmakers Tee Up Bills on PBMs, Drug Pricing This Year

Radar On Market Access: 2020 Could Be 'Wild Year' for Consolidated PBMs

MMIT Reality Check on Cystic Fibrosis (Jan 2020)

Perspectives on UnitedHealth/Diplomat Deal

Radar On Market Access: Health Care Deals May Slow in 2020, but Government Markets Remain Hot

Radar On Market Access: Navajo Nation, Molina Partner on Medicaid Managed Care in New Mexico

MMIT Reality Check on Growth Hormone Deficiency (Jan 2020)

Trends That Matter for New Acute Migraine Medications

MMIT Reality Check on Ovarian Cancer (Dec 2019)

Perspectives on Dual Eligible SNPs

Radar On Market Access: Health Insurers Receive Multiple Gifts In Year-End Spending Package

Radar On Market Access: Uptake of New MA Supplemental Benefits Remains Modest in 2020, Report Says

Trends That Matter for New Sickle Cell Medications

Radar On Market Access: New Sickle Cell Medications Offer Both Opportunities and Challenges

MMIT Reality Check on Migraine (Dec 2019)

Trends That Matter for Anti-VEGF Market

Radar On Market Access: Patient-Reported Outcomes Play Key Role in New Multiple Sclerosis Value-Based Contract

Radar On Market Access: UnitedHealth Makes Deal to Buy Diplomat as Industry Consolidation Enters 'Second Phase'

MMIT Reality Check on Multiple Myeloma (Dec 2019)

Perspectives on Preferred Cost-Sharing Pharmacy Networks

Radar On Market Access: CMS Struggles With New Medicare Plan Finder 'Glitches'

Radar On Market Access: Highmark's New Hemophilia Initiative Aims to Improve Care, Reduce Costs

MMIT Reality Check on Chronic Lymphocyctic Leukemia (Dec 2019)

Trends That Matter for New Cystic Fibrosis Medication

Radar On Market Access: New Acute Migraine Medications May Not Shake Up Formularies

Radar On Market Access: Amid Budget Standoff, North Carolina Delays Medicaid Transformation

MMIT Reality Check on Crohn's Disease (Nov 2019)

Perspectives on Racial Bias in Optum Risk-Prediction Algorithm

Radar On Market Access: Trump Administration's Transparency Rules Are Part of Larger Effort

Radar On Market Access: National and Regional Players Make Dual Eligible SNP Moves

MMIT Reality Check on Atopic Dermatitis (Nov 2019)

Trends That Matter for 2020 Star Quality Ratings

Radar On Market Access: CVS Health, Cigna Tout Benefits of PBM-Insurer Integration

Radar On Market Access: Independent Pharmacies Push Bill to Increase Access to Part D Preferred Networks

MMIT Reality Check on Immune Globulin (CIDP) (Nov 2019)

Perspectives on How Drug Pricing Legislation Impacts Innovation

Radar On Market Access: 'Breakthrough' Cystic Fibrosis Drug Could See High Demand

Radar On Market Access: Analysts Question Issues Surrounding Beovu's Uptake in Full Anti-VEGF Market

MMIT Reality Check on Uveitis (Nov 2019)

Trends That Matter for IL-17 Use in Psoriasis

Radar On Market Access: Some Insurers Cover Acupuncture to Combat Opioid Epidemic

Radar On Market Access: Study Highlights Racial Bias in Optum Risk-Prediction Algorithm

MMIT Reality Check on Carcinoid Syndrome (Nov 2019)

Perspectives on Pelosi Drug Pricing Legislation

Radar On Market Access: CMS Updates Medicare Plan Finder Amid Advocates' Concerns

Radar On Market Access: Walgreens Joins Centene in Pact With Cloud-Based PBM RxAdvance

MMIT Reality Check on ADHD (Oct 2019)

Trends That Matter for Parkinson's Disease Medications

Radar On Market Access: Low-Cost Enhanced PDP Offerings See Growth in 2020

Radar On Market Access: More Than 80% of Medicare Advantage Enrollees Are in High Star Plans, CMS Reports

MMIT Reality Check on Hepatocelluar Carcinoma (Oct 2019)

Perspectives on New Solutions to Finance High-Cost Treatments

Radar On Market Access: Would Drug Pricing Legislation Impact Innovation?

Radar On Market Access: Study Shows Growing IL-17 Use in Psoriasis

MMIT Reality Check on Psoriasis (Oct 2019)

Trends That Matter for AML Therapy Class

Radar On Market Access: PhRMA, Conservatives Criticize Pelosi Drug Pricing Legislation

Radar On Market Access: CMS Projects Record-High Medicare Advantage Enrollment in 2020

MMIT Reality Check on IBS-C (Oct 2019)

Perspectives on Changes to Addiction Treatment Privacy Rules

Radar On Market Access: Despite Approval of New Parkinson's Drugs, Plans Still Prefer Generics

Radar On Market Access: Does New Medicare Plan Finder Make Part D Plans Tougher to Parse?

MMIT Reality Check on Soft Tissue Sarcoma (Sep 2019)

Trends That Matter for High-Touch Care Management for Chronic Conditions

Radar On Market Access: Industry Groups Praise OIG Report on Medicare Part D Rebates

Radar On Market Access: Health Plans Are Hesitant to Add New Narcolepsy Drugs to Formularies

MMIT Reality Check on Immune Thrombocytopenic Purpura (Sep 2019)

Perspectives on Million-Dollar Treatments

Radar On Market Access: AML Therapy Class Has Seen Boom Over Past Couple of Years

Radar On Market Access: New Solutions to Finance High-Cost Treatments May Raise New Questions

MMIT Reality Check on Schizophrenia (Sep 2019)

Trends That Matter for RM/AT Products

Radar On Market Access: Novartis’ Zolgensma Crisis May Not Impact Pickup

Radar On Market Access: Insurers Welcome Changes to Addiction Treatment Privacy Rules

MMIT Reality Check on Breast Cancer HER2+ (Sep 2019)

Perspectives on Trump's Drug Importation Plan

Radar On Market Access: Pill Club, CVS Dispute Raises Larger Questions

Radar On Market Access: Pediatric Managed Medicaid ACO Leverages Pharmacists to Improve Care

MMIT Reality Check on Dry Eye (Aug 2019)

Trends That Matter for Hepatitis C Drugs

Radar On Market Access: Health Insurers Turn to Data Analytics to Combat Fraud, Waste and Abuse

Radar On Market Access: Large Employers Are Concerned About Million-Dollar Treatments

MMIT Reality Check on Hemophilia A (Factor VIII) (Aug 2019)

Perspectives on Blockchain Technology

Radar On Market Access: PBMs Offer High-Touch Care Management for Chronic Conditions

Radar On Market Access: Employers Seek Health Plan, PBM Help to Drive Innovation

MMIT Reality Check on Breast Cancer HER2- (Aug 2019)

Trends That Matter for Medicare Part D Costs

Radar On Market Access: More Than 1,000 RM/AT Products Are in Pipeline

Radar On Market Access: Trump's Drug Importation Plan Faces Significant Hurdles

MMIT Reality Check on Ulcerative Colitis (Aug 2019)

Perspectives on Electronic Real-Time Benefit Tool

Radar On Market Access: Senate Drug Pricing Legislation Takes Wide-Reaching Approach

Radar On Market Access: Congress Eyes Measures That Could Affect PBMs

MMIT Reality Check on Merkel Cell Carcinoma (Aug 2019)

Trends That Matter for CMS's Oncology Care Model

Radar On Market Access: Can Louisiana’s Hepatitis C Drug Payment Model Be Replicated?

Radar On Market Access: Will Blockchain Transform Relationships Industry Wide?

MMIT Reality Check on Parkinson's Disease (Jul 2019)

Perspectives on New York's Pricing Transparency Bill

Radar On Market Access: Post-Rebate Rule, Trump Administration Mulls 'Any and All Tools'

Radar On Market Access: Plans Offer More $0 Copay Drugs to Boost Adherence

MMIT Reality Check on Kidney Cancer (Jul 2019)

Trends That Matter for Oncology Biosimilars Management

Radar On Market Access: In Win for Managed Care, Trump Administration Drops Rebate Rule

Radar On Market Access: In Medicare Part D, Generic Drugs May Not Always Be Cheaper

MMIT Reality Check on Bipolar Disorder (Jul 2019)

Perspectives on the First NASH Drugs

Radar On Market Access: Plans Must Cover PrEP at No Cost After USPSTF Recommendation

Radar On Market Access: Expensive Drugs Launched After OCM Baseline Period Are Hamstringing Providers, Study Shows

MMIT Reality Check on Psoriatic Arthritis (Jul 2019)

Trends That Matter for Oncology

Radar On Market Access: States Plow Ahead on 'Subscription' Models for Hep C Therapy

Radar On Market Access: New York Bill Targets on Pricing Transparency from PBMs

MMIT Reality Check on Acute Lymphoblastic Leukemia (Jun 2019)

Perspectives on Express Script's "Digital Health Formulary"

Radar On Market Access: CMS Requires Part D Plans to Offer RTBT

Radar On Market Access: Troy Medicare Aims to Launch Pharmacist-Centered Model in NC

MMIT Reality Check on Hemophilia A or B With Inhibitors (Jun 2019)

Trends That Matter for COPD Medications

Radar On Market Access: Magellan Rx Initiates Oncology Biosimilars Program

Radar On Market Access: Payers Are Wary as First NASH Drugs May Hit U.S. Market Soon